Developing a broadly neutralising antibody therapeutic to combat SARS-CoV-2 1SHARES Share via Pinterest Reddit Buffer Xing WhatsApp Flipboard Posted: 31 March 2021 | Dr Laura Walker (Adagio Therapeutics) | No comments yet With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and how a lead antibody candidate has been selected. The mobilisation of the pharmaceutical industry to identify and develop therapeutics for patients with COVID-19 has led to a wide range of innovative treatments. One key class of biopharmaceuticals that have shown great potential is antibodies. With regular news updates and feature articles, our COVID-19 hub has everything you need to keep up to date with R&D during the pandemic. Click below to visit: COVID-19 hub Recently, Adagio Therapeutics published data showing the success of its lead antibody candidate in vitro and in vivo. With a focus on ensuring success against variants of SARS-CoV-2, Walker explained how the researchers conducted pre-clinical studies to prove the new treatment is effective and why antibodies are vital for ending the pandemic. To read this article in full, please complete the form below: First Name * Surname * Job Title * Organisation * Town/City * Country * —Please choose an option—AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCook IslandsCosta RicaCote D'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFaeroe IslandsFalkland IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadaloupeGuamGuatemalaGuineaGuinea-BissauGuyanaHaitiHeard and McDonald IslandsVatican CityHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKoreaKosovaKuwaitKyrgyz RepublicLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian TerritoryPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandPolandPortugalPuerto RicoQatarReunionRomaniaRussiaRwandaSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbia and MontenegroSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSpainSri LankaSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudanSurinameSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor Outlying IslandsUnited States of AmericaUruguayUS Virgin IslandsUzbekistanVanuatuVenezuelaVietnamWallis and Futuna IslandsWestern SaharaYemenZambiaZimbabwe Email * Telephone * This specialist content is provided to you free-of-charge thanks to the kind support of Agilent I would like to receive relevant information and insights from the sponsor(s) of this content *—Please choose an option—YesNo By clicking submit you confirm that you accept our terms and conditions and privacy policy. Related topicsAntibodies, Antibody Discovery, Assays, Biopharmaceuticals, Drug Leads, In Vitro, In Vivo, Proteomics Related conditionsCovid-19 Related organisationsAgilent, US Food and Drug Administration (FDA)
